Prevention & care

SIBO: classical malabsorption, breath testing, IBS controversy, methanogen terminology, and treatment uncertainty

6 sources · Latest source check 2026-10-13 UTC

On this page

Small-intestinal bacterial overgrowth refers to excessive bacteria, or changes in bacterial populations, in the small intestine associated with a clinical problem. Classical cases occur with altered anatomy or intestinal stasis and can cause maldigestion or malabsorption. Extending this explanation to every case of bloating or IBS is a separate and disputed claim.[3][1]

Similar vocabulary, different questions

Similar vocabulary, different questions
Context	What needs distinguishing
Classical SIBO	Anatomical or motility predisposition with digestive/nutritional consequences.[1]
IBS-associated SIBO hypothesis	A disputed explanation for symptoms without the classical malabsorption setting.[4]
Breath-test positivity	A gas measurement requiring clinical interpretation.[2]
IMO	A separate label for methane-producing organism overgrowth in constipation-related assessment.[2]

Anatomy and movement help explain established clinical settings

MedlinePlus identifies postoperative loops, intestinal pouches or obstruction, disorders that reduce intestinal movement and selected immune deficiencies as possible settings. Excess bacteria can interfere with nutrient absorption. A history of surgery or motility disease helps establish why overgrowth is plausible, but does not diagnose the cause of each new symptom without assessment.[1]

The symptom list is shared with many other digestive conditions

Bloating, abdominal discomfort, gas and diarrhea can occur; fatty stools or weight loss may indicate more substantial digestive consequences. MedlinePlus describes examination and selected blood, nutrient, stool, endoscopic or breath tests. These symptoms and tests are pieces of an investigation, rather than a symptom checklist that proves one microbial explanation.[1]

Breath testing measures microbial gases indirectly

The ACG guideline describes measuring hydrogen or methane after a test carbohydrate. The gases arise from microbial fermentation and reach expired breath. This is an indirect measurement, rather than a count or map of organisms inside each intestinal segment. Its recommendations depend on symptoms and clinical setting; it advises against testing asymptomatic PPI users simply because they take that medicine.[2]

Fast transit can complicate the location inferred from lactulose

The 2024 critical appraisal explains that lactulose can reach the colon and be fermented there before a proposed test cutoff, especially with rapid transit. An early hydrogen rise can therefore reflect transit rather than small-intestinal overgrowth. It cites combined transit-imaging and breath measurements supporting this concern in IBS patients. The location of gas production is part of the diagnostic question.[4]

The dispute has a population and a mechanism

The appraisal acknowledges classical SIBO in predisposed malabsorptive patients while challenging the IBS hypothesis and its testing practices. This is more specific than saying all bacterial overgrowth is imaginary. Conversely, proving that classical disease exists does not validate the same test interpretation for all otherwise unexplained bloating. The article’s population distinction matters.[4]

AGA also emphasizes unresolved definitions and limited strategies

AGA’s 2020 expert review describes inconsistent definitions and limited understanding of normal small-intestinal microbial populations. It does not support fecal calprotectin as a SIBO detector. A general stool inflammation result cannot substitute for evaluating this different question. Its best-practice statements were developed through literature review and author discussion, rather than a new randomized experiment.[3]

The underlying cause and nutritional consequences need attention

AGA recommends addressing underlying causes where possible, correcting nutritional deficits and considering antibiotics, especially with significant maldigestion or malabsorption. It also describes a limited evidence base for antibiotic strategies and risks from prolonged broad-spectrum treatment. Improvement after an antibiotic in IBS does not, by itself, establish that confirmed SIBO eradication caused that improvement.[3]

The frequently cited rifaximin review has important design limits

Gatta and Scarpignato’s 2017 review included 32 studies and 1,331 patients. The pooled intention-to-treat eradication estimate was 70.8%, but heterogeneity was substantial. This proportion combines different study settings and should not be presented as a guaranteed success rate for an individual or proof that everyone with bloating benefits from treatment.[5]

Symptom improvement was evaluated in only a subset of studies and had especially wide uncertainty. The authors described the underlying study quality as generally poor and called for better randomized trials. Test normalization, meaningful symptom improvement and sustained freedom from recurrence are different outcomes; a pooled eradication statistic answers only part of the care question.[5]

A named condition does not establish a universal protocol

A conditional antibiotic recommendation for diagnosed SIBO does not establish an optimal repeat-treatment schedule or validate a branded combination of antimicrobials and restrictive diets. The ACG and AGA documents support context-specific clinical assessment. Full contemporary treatment comparisons and long-term adverse effects remain necessary before stronger general conclusions.[2]

A gas threshold is an interpretation rule, not direct bacterial counting

Hydrogen and methane breath tests measure gases after a swallowed substrate such as glucose or lactulose. The2017 consensus used a hydrogen rise of at least20 parts per million by90 minutes as a positive SIBO criterion and methane at least10 parts per million as methane-positive. Parts per million describes gas concentration. These thresholds standardize interpretation; they do not directly count organisms, locate each gas producer or overcome the transit limitations described above.[6]

Evidence & uncertainty

Professional guidance disagrees. ACG’s 2020 guideline conditionally supports breath testing in several symptomatic settings with very-low-certainty evidence. A 2024 ESNM/ANMS-endorsed appraisal rejects reliance on breath testing for the SIBO explanation of IBS. Neither a positive result nor a popular “SIBO protocol” removes that uncertainty.[2][4]

Selected-source overview · Independent review pending

Published questions

Does bloating alone establish small intestinal bacterial overgrowth?

Selected-source overview · Independent review pending. Read the evidence context.

Symptoms overlap with other conditions.[1]

Evidence behind this answer

Small bowel bacterial overgrowth
agency condition or prevention explanation · 2026
Original indexed full clinical page inspected · April 2026: classical risks, symptoms, investigations and nutritional consequences